SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
41,000
-1,300 (-3.07%)
At close: May 27, 2026
Market Cap3.32T +6.1%
Revenue (ttm)665.42B +66.4%
Net Income-83.29B
EPS-1,063.58
Shares Out 78.46M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume196,504
Open41,450
Previous Close42,300
Day's Range40,200 - 42,100
52-Week Range39,400 - 61,300
Beta0.93
AnalystsSell
Price Target37,200.00 (-9.27%)
Earnings DateAug 12, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 917
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

In 2025, SK bioscience's revenue was 651.37 billion, an increase of 143.46% compared to the previous year's 267.55 billion. Losses were -57.42 billion, 6.58% more than in 2024.

Financial Statements